Back to Agenda
Session 2: From Detection to Prediction. Rethinking Signal Management in the Age of AI
Session Chair(s)
Tarek Hammad, MD, PhD, MS, MSc, FISPE
Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV, Takeda Pharmaceuticals, United States
Signal management is entering its first real methodological shift in decades. The Innovative Health Initiative (IHI) has made this shift explicit. IHI Call 11, Topic 3, "AI-Powered Signal Detection in Pharmacovigilance," funds the development and validation of AI-based methods for early signal detection and risk prediction across heterogeneous data sources. The topic also calls for common data models, practical implementation guidance, and recommendations developed with regulators on how AI methods should be qualified for pharmacovigilance use. By April 2027 the selected consortium should be operational, which places DIA at an ideal point in the arc. The work, or at least clear plans, will be underway. This creates a genuine opportunity for a session to convene the people building these methods, the people who will have to run them in a regulated safety system, and the regulators who will have to accept or reject their output. The functional focus is signal detection and risk prediction, positioned inside the wider question of safety governance and accountability.
Learning Objective : At the conclusion of this session, participants should be able to: - Implement effective pharmacovigilance strategies for combination products, including medication error evaluation and incorporation of safety insights into device design and user instructions
- Differentiate risk escalation pathways and determine when safety concerns warrant device risk management actions versus formal
Have an account?